ORIGINAL RESEARCH

miR-132 can inhibit glioma cells invasion and migration by target MMP16 in vitro

Hangzhou Wang^{1,2,*} Xue-tao Li^{1,*} Chun Wu¹ Zhi-wu Wu¹ Yan-yan Li¹ Tian-quan Yang¹ Gui-lin Chen¹ Xue-shun Xie¹ Yu-lun Huang¹ Zi-wei Du¹ You-xin Zhou¹

¹Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China; ²Department of Neurosurgery, Children's Hospital Affiliated to Soochow University, Suzhou, Jiangsu, People's Republic of China

*These authors contributed equ to this work



Correspondence: You-Xin Zhou Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, Jiangsu 215006, People's Republic of China Tel +86 139 1552 2828 Fax +86 512 6778 1170 Email zhouyouxin@suda.edu.cn

submit your manuscript | www.dovepress.com Dovencess http://dx.doi.org/10.2147/OTT.\$79282

Abstract: Gliomas are the most common malignant prima, brain tumors, nd new clinical biomarkers and therapeutic targets are imminently realized. roRNAs hiRNAs) are a novel class of small non-coding RNAs (~22nt) iny red in the reg. tion of various biological processes. Here, by using real-time polymer, chain ction, mik AA-132 was found to the predition of the target genes of be significantly deregulated in glioma tissu Base between miR-132 and matrix gnificant as iatio miR-132, we hypothesized that there is metalloproteinase (MMP) 16 (MT3-2 AP), rotein of the AMP family. We showed that the up-expression of miR-132 inhibited cell migrate and invasion in the human glioma cell lines A172, SHG44, and U87. Furtharmore, the overexpression of miR-132 reduced the expression of MMP16 in A172, SHG4 and U87 cells Taken together, our study suggested that miR-132 affects glioma cell migratio nd invasion MMP16 and implicates miR-132 as a metastasisinhibiting miRNA in gliomas

microRN, 13-MMP, invasions Keywords: glio

Intr ctio

common malignant primary brain tumors and are characterized Gl mas ar he mos ation, robust angiogenesis, and invasion into the surrounding ncre orain tissue.¹ Despite aggressive surgery, radiation, and chemotherapy, the norm vival of glioblastoma patients is 12–15 months.² Since tumor invasion is a median ajor reason for treatment failure,^{3,4} the development of novel therapeutic strategies d at limiting or reducing the ability of invasion of glioma cells could have a deep effect on patient outcome.

MicroRNAs (miRNAs) are short single-stranded nucleotide RNA molecules, which regulate gene expression by binding to the 3'-UTRs translated regions of their target mRNA molecules, to repress transcription or induce mRNA degradation.^{5,6} miRNA controls cell growth, proliferation, metabolism, and apoptosis.^{7,8} Indeed, specific miRNA dysregulation has been shown to correlate with particular types of cancer.9,10 For example, miR-16, lower expressed in glioma cells, suppresses Bcl-2¹¹ and miR-145, overexpressed in metastatic glioma cells, suppresses ADAM17.12

Matrix metalloproteinase (MMP) 16 (membrane type 3 MMP [MT3-MMP]) is a membrane-type metalloprotease that functions in activating proMMP2 (gelatinase A) into its active form as the zymogen is excreted out of the cell.¹³ Therefore, a zymogram depicting the gelatinase activity of activated MMP2 would be an indirect mechanism of determining the activity of MMP16. MMP2 can cleave collagen IV of the basement membrane and is implicated in cancer metastasis.¹⁴ It is therefore not surprising that high MMP16 expression has been associated with increasing invasiveness in gastric cancer,¹⁵ hepatocellular carcinoma,¹⁶ prostate cancer,¹⁷ as well as melanoma cells.¹⁸

OncoTargets and Therapy 2015:8 3211-3218 © 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution — Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on

how to request permission may be found at: http://www.dovepress.com/permissions.php

3211

hsa-miR-132 gene is located in chromosome 17 (1953202–1953302) with 100 bp in miRbase. In the last several years, many studies have found the deregulated expression of miR-132, which has been implicated in the development and progression of various cancers. For instance, miR-132 can act as a tumor suppressor and inhibit cell proliferation in breast cancer.¹⁹ Furthermore, the dysregulation of miR-132 has been found in primary osteosarcoma,²⁰ Alzheimer's disease,²¹ prostate cancer,²² and pancreatic cancer.²³ But the function of miR-132 in regulating glioma cell migration and invasion remains unexplored.

In our study, the expression of miR-132 in glioma tissues compared with normal brain tissue was studied by real-time reverse transcription polymerase chain reaction (RT-PCR). We demonstrated that miR-132 inhibits glioma cell invasion by directly targeting the three prime untranslated region (3'-UTRs) of MMP16, at the time impair activation of MMP2. Our results suggest that downregulation of miR-132 plays an important role in enhancing the invasion of glioma cells.

Materials and methods Cell lines and cell culture

The following three human glioma cell lines were used: U87MG, SHG44, and A172. They were maintained to Dulbecco's Modified Eagle's Medium (DMEM) (U87MO A172) or RPMI-1640 (SHG44) medium supplemented with 10% fetal bovine serum (FBS) and 100 U/r2 penullin/ streptomycin. All cultures were maintained in a hum 4^af od atmosphere of 5% CO₂ at 37°C.

Clinical specimens

Glioma tissues were obtain from therapy tic procedures performed as routine c Ical menagement a our institution. Tissue samples re r ected during surgery and in lique nitroge for subsequent total immediately frozz w-grade glioma tissues RNA extraction . A to of ele <u>high-g</u>rade glioma tissues (glioma (glioma grans I–II) grades III–IV), eight nonneoplastic brain specimens were included in our st

Transfection of miRNA mimics or inhibitor

Glioma cells were seeded in six-well plates at 50% confluence without antibiotics on the day before transfection. Transfection with miR-132 mimics (UAACAGUCUACAGCCAU GGUCGACCAUGGCUGUAGACUGUUAUU) or miRNA mimics negative control (UUCUCCGAACGUGUCA CGUTTACGUGACA CGUUCGGAGAATT) and miR-132 inhibitor (5'-3'CGACCAUGGCUGUAGACUGUUA) or miRNA inhibitor negative control (5'-3'CAGUACU UUUGUGUAGUACAA) was performed using Lipofectamine 2000 reagent (Thermo Fisher Scientific, Waltham, MA, USA). Transfection complexes were prepared according to the manufacturer's instructions.

RNA extraction and quantitative real-time PCR

Total RNA was isolated from tumor sample and glioma cell lines with TRIzol reagent (Thermo Fisher Scientific), and their RNA concentrations were measured with an Eppendorf BioPhotometer at 260 nm and 280 m (A260 80). cDNA was synthesized with the ReverTrace®qPCR Rekit (FSQ-101; Toyobo, Osaka, Japan) Keal-tin, PCR an yses were performed with SYBR[®] Cleen Real-Time PC Master Mix (QPK-201; Toyobo). White non of miR-132 was peroop reasone PCP ARNA kit (RiboBio, formed with a step Guangzhou, P S Republic S Cana). Operation is based uctions. The primer pairs for MMP16 on manufacturer's in. GAAGAC GTTGGATTTCGTG-3' and antiwere se 5'-GTCAGTCGGTGGAAGGTAGC-3', and those for sens raldehyde 3 hosphate dehydrogenase (GAPDH) were gly sense GGGTC GAACCATGAGAAGT-3' and antisense ACTGTGGTCATGA-3'. RT-PCR was done 5'-GGCA pated real-time instrument (ABI7300) for 40 cycles in 115 seconds at 94°C and of 1 minute at 58°C.

h vitro matrigel invasion assay

Matrigel chambers (BD Biosciences) were used to determine the effect of miR-132 on invasiveness according to the manufacturer's instructions. A total of 5×10^4 cells, after being transfected 36 hours, were resuspended in basic DMEM culture medium, supplemented with 0.5% FBS, and added 200 μ L to the upper chamber of a transwell system (8 µm pore size, Corning 3422), while the lower chamber was filled with 0.5 mL of complete medium that served as a chemoattractant. After incubation for 24 hours at 37°C, invasive cells, which had the ability to push themselves through the 8 µm pores and grow on the lower surface, were fixed with 100% methanol and stained with 1% toluidine blue (Sigma-Aldrich Co.) before counting under an inverted microscope. All the experiments were done in duplicate, and results were expressed as mean \pm SEM of three independent experiments.

Western blotting

Forty-eight hours after miRNA mimics or miRNA inhibitor transfection, total proteins were isolated from tissues and cell lines with radioimmunoprecipitation (RIPA) lysis buffer

miR-132 affects glioma cell migration and invasion

(P0013B, Beyotime, People's Republic of China). The supernatants containing the whole protein extracts were obtained after centrifugation of the lysates at $12,000 \times g$ for 20 minutes at 4°C. The protein concentrations were determined by enhanced bicinchoninic acid protein assay kit (Beyotime). Heat-denatured protein samples (50 µg per lane) were resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to an Immobilon-P transfer membrane (EMD Millipore). The membrane was blocked in 5% non-fat dry milk in Tris-buffered saline (pH 7.4) containing 0.05% Tween-20 to block nonspecific binding, followed by incubation overnight at 4°C with a primary rabbit polyclonal antibody against human MMP16 (1:200, Boster, People's Republic of China), MMP2 (1:250, Santa Cruz Biotechnology Inc., Dallas, TX, USA), and was blotted with goat anti-rabbit immunoglobulin G (1:3,000, Santa Cruz Biotechnology Inc., USA). Then GAPDH was used as a loading control. Signals were detected by secondary antibodies labeled with HRP, and the bound antibody was detected with the use of enhanced chemiluminescence detection reagents (Beyotime) according to the manufacturer's instructions.

Plasmids construction and dual-lucife reporter assay

We entrusted Shanghai Ltd. to construct pGL_MMP1 amplifying 3'-UTR of MMP16 gene ha Joring he mil 132 binding site predicted by the Tars Scan ww targetscan.org) and subsequently oning to the pGL3 on, Fitchbu control vector (Promega Corpe WI, USA) at the Xbal site immediately ownship of firefly uciferase. pGL3-MMP16-mut, which has three sismatch mutations in the miR-132 seed complementary site, was generated to be a negative control. For the luciferase assay, 293T cells were cultured 12-we plates a reach was cotransfected r pGL. V P16 or pGL3-MMP16-mut, with 4001 ofeit (Promega Corporation), and 50 nmol/L 50 ng pRL-T mics or NC. The pRL-TK Renilla luciferase of miR-13 plasmid was used as an internal control to correct differences in both transfection and harvest efficiencies.

Forty-eight hours after transfection, firefly and Renilla luciferase activities were measured using the dual-luciferase reporter assay (Promega Corporation). The results were expressed as relative luciferase activity (firefly luciferase/ Renilla luciferase).

Statistical analysis

Data are presented as mean \pm standard deviation. The data were analyzed using the SPSS 12.0 Windows version

software. Statistical analyses were done by analysis of variance or Student's *t*-test. *P*-value <0.05 was considered statistically significant.

Result

Expression of miR-132 is lower in glioma tissue compared to normal brain tissues

To determine the role of miR-132 in glioma tissues, we used real-time PCR analyses to determine the expression of miR-132 in eleven low-grade glioma tissues and 12 high-grade glioma ssues. As shown in tissues compared to eight normal Figure 1A, miR-132 expressi I levels we significantly decreased in glioma tissues converted to norm brain tissues. In addition, we found that the envession miR-132 was lower in glioma cell mes corpared mal brain tissues (Figure 1B). The downey ation of miR-132 in glioma tisa cell line sugger that miR-132 may be as sues and glig a potentizita, et in glioma apy.

mi7.132 can heibit invasion of glioma cells in order to understand the effect of miR-132 on glioma ell invasion and migration, we used miR-132 mimics and n ibitors to affect human glioma U87, SHG44, and A172 cells. So enty-two hours after transfection with miR-132 compared enty-two hours after transfection with miR-132 compared enty-two hours after transfection with miR-132 compared and counted (Figure 2A and B). In both cell lines, miR-132 could decrease the number of cells that invaded compared to controls. Taken together, these data indicate that miR-132 may be as a regulatory molecule concern cell migration and invasion in vitro.

Expression of MMP16 mRNA in glioma tissues

Real-time PCR analyses showed that the expression of MMP16 mRNA was dramatically higher in eleven low-grade glioma tissues and 12 high-grade glioma tissues compared to eight normal brain tissues. The result is shown in Figure 1C. Here, our result showed that MMP16 mRNA is higher expression in glioma tissues, compared that the results of miR-132 in glioma tissues suggest that the expression of MMP16 mRNA expression is inversely related to the miR-132.

miR-132 downregulates the expression of MMP16 mRNA

To explicit the mechanism by which miR-132 inhibited cell migration in glioma cells, we founded miR-132 targets using the algorithms TargetScan5 and miRBase and found that




Figure I The expression of miR-132 is lower in glioma tissue compared to those norma es and the expression of MMP16 in glioma tissues. Notes: (A) miR-132 expression in glioma tissues and normal brain specimens. The evels of miR-132 were measured by real-time PCR assay. (B) In MMP16 mRNA n. The result showed that the genes expression is higher than normal brain tissues expression in glioma tissues and normal brain tissues, we used the qPCR s 32 expr a cell lines U87, A172, and SHG44 and normal brain tissues. The relative expression (P<0.05). Total RNA was extracted using TRIzol reagent. (C) mi ion in gli presented of miR-32 was calculated by using a $2^{-\Delta\Delta C_t}$ method. The data P < 0.05 compared to the control. mean ± SC Abbreviations: MMP16, matrix metalloproteinase 16; PCR PCR, quantitative PCR; SD, standard deviation. mera

MMP16 might play a role in cell ____grav and invasi . We use RT-PCR assay and qPCR stems. Tran. ction of glioma cells with miR-132 mimig gnificantly decreased the expression of MMP16 mRNA glior cells compared to levels in control miR expressing ce Figure 2 and B). The above results showed at M target gene of miR-132 P16 m be to promote e gliom cell migration and invasion.

MMP16 as a activator of MMP2 can activate the expression of MMP2 protein levels


To validate whether miR-132 can affect the expression levels of MMP16 protein, we measured the protein expression levels of MMP16 in response to the effect in the miR-132 expression level in U87, A172, and SHG44 by transfection. We found that protein expression level of MMP16 was downregulated and upregulated by miR-132 mimics and miR-132 inhibitor transfection, respectively (Figure 4).

miR-132 can directly downstream the target gene of MMP16

miR-132 is predicted to target MMP16 (MT3-MMP) (www. microRNA.org), which is a potential activator of MMP2.^{23,24} We used Western blot to validate the hypothesis. The results showed that miR-132 can activate the expression of MMP2 protein by regulating the expression of MMP16 (Figure 4). Up-miR-132 inhibits invasion in human glioma cells by directly downregulating MMP16 expression. The luciferase assay revealed reduced relative luciferase activities in 293T cells stably, overexpressing miR-132 following transfection of MMP16 3'-UTR (Figure 5A and B) (P<0.05).

Discussion

In our study, we found lower levels of miR-132 in glioma cancer tissues than in normal brain tissues and in glioma cells than in normal brain tissues. Furthermore, we have found that miR-132 could inhibit glioma cell invasion








Figure 3 The expression of MMP16 in glioma cells at after 48 hours transfection.

Notes: (A and B) The expression of MMP16 mRNA in glioma cells (U87, A172, and SHG44) at after 48 hours transfection with RT-PCR system and qPCR systems (premiR-132 as miR-132 mimics; anti-miR-132 as miR-132 inhibitor). *P<0.05; **P<0.01.

Abbreviations: MMP16, matrix metalloproteinase 16; RT-PCR, reverse transcription polymerase chain reaction; qPCR, quantitative PCR; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, normal.




Figure 4 Up-miR-132 can reduce the protein expression of MMP16 and MMP2 in U87, A172, and SHG44 cell lines by Western blot systems (pre-miR-132 as miR-132 mimics; anti-miR-132 as miR-132 inhibitor).

Note: *P<0.05; **P<0.01.

Abbreviations: MMP, matrix metalloproteinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, normal control.




Figure 5 The relation of miR-132 and MMP16 by luciferase assay. Notes: (A) Analyzing the homology between the MMP16 sequence and miR-132. (B)

up-miR-132 following transfection of MMP16 3′-UTR (**P<0.05). Abbreviations: MMP16, matrix metalloproteinase 16; UTR, untranslated region; FL, file y luciferase; RL, milla luciferase; NC, normal control.

and migration in glioma cells. Glioma cells by trans cteu miR-132 mimics decreased tumor cell migration and i vasion, while inhibition of transfecting mi inhibi produced the opposite result. Neverthe ess, whe her mik 132 inhibits tumor invasion and meta. sis gn vivo still remains to be investiged, because such study is hampered at present by the lacour experime strategy for stably increasing or cilencing m NAs over extended periods of time.

We further showed that the function of miR-132 inhibits nigration properties by reducing glioma cell invasion an M. P. g. e, MMP16. MMP16 is a the express -anchood MMP tat is able to activate MMP2 membrz a succe aggests the functional relevance for invaof MMP16, the downregulation of glioma cell migration. The previous report showed that decreasing MMP16 levels efficiently inhibit cell invasion of glioma cells.25 As MMP2 is activated by MMP16, this would be an indirect indication of the function of MMP16. MMP16 was also found to possess proteolytic activity against ECM components such as type III collagen. It is possible that MT3-MMP is involved in the turnover of ECM in the normal brain and astrocytic tumor tissues.26,27

In conclusion, our data suggested that miR-132 plays a key role in the malignancy of glioma cells possibly by direct

regulation of MMP16 protein expression, which affects ghour a cell migration and invasion. Our data suggested that miR-132 may be a potential therapeutic target for preventing GBM invasion and metastasis. However, further study is needed to determine if MMP16 activity is influenced by miR-132 in vivo in glioma.

luciferase assay revealed reduced relative luciferase activities in 293T cell stably

Acknowledgments

We thank our central lab for providing technical instruction and assistance. This work was partly supported by National Science Foundation (Grant No 81372689) and the Foundation of Health Department in Jiangsu Province (Grant No K201106).

Disclosure

The authors report no conflicts of interest in this work.

References

- Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. *Genes Dev.* 2007;21:2683–2710.
- Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359: 492–507.
- Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. *J Clin Oncol.* 2003;21:1624–1636.
- Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. *J Clin Oncol.* 2005;23:2411–2422.

- Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 2005;352:987–996.
- Holland EC. Gliomagenesis: genetic alterations and mouse models. *Nat Rev Genet*. 2001;2:120–129.
- Miska EA. How microRNAs control cell division, differentiation and death. *Curr Opin Genet Dev.* 2005;15(5):563–568.
- Esquela-Kerscher A, Slack FJ. Oncomirs microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–269.
- Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. *Nature*. 2005;435(7043):834–838.
- Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci* U S A. 2006;103(7):2257–2261.
- Yang TQ, Lu XJ, Wu TF, et al. MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/ MMP9 signaling pathway. *Cancer Sci.* 2014;105(3):265–271.
- Yong Lu, Michael Chopp, Xuguang Zheng, Mark Katakowski, Benjamin Buller, Feng Jiang. MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. *Oncology Reports*. 2013; 29:67–72.
- Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. *Am J Pathol.* 1999;154:417–428.
- 14. Rowe RG, Weiss SJ. Breaching the basement membrane: who, when and how? *Trends Cell Biol*. 2008;18:560–574.
- Lowy AM, Clements WM, Bishop J, et al. Beta-Catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. *Cancer Res.* 2006;66:4734–4741.
- Arai I, Nagano H, Kondo M, et al. Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasion. *Hepa* gastroenterology. 2007;54:167–171.
- Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ. Characterization of expression of matrix metalloproteinases and tissue inhibiter of metalloproteinases in prostate cancer cell lines. *Prostate Concernentatic Dis.* 2003;6:15–26.

- Ohnishi Y, Tajima S, Ishibashi A. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells. *Eur J Dermatol*. 2001;11:420–423.
- Shuai Li, Huimin Meng, Feng Zhou, et al. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. *Pathology – Research* and Practice. 2013;179–183.
- Yang J, Gao T, Tang J, Cai H, Lin L, Fu S. Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma. *Mol Cell Biochem.* 2013;381(1–2):9–15.
- Xia H, Qi Y, Ng SS, et al. MicroRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. *Brain Res.* 2009;1269:158–165.
- 22. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT 10MP-2) gene from a human placenta cDNA library. MTMMPs from a unique membrane-type subclass in the MMP family. *J Biol Chem.* 1995;270:2013–23020.
- Nakada M, Yamada A, Takino T. Supression of men grane-type 1 matrix metalloproteinase (MMD-media 1) MMP-2 and vation and tumour invasion by testicant and its splich available grane product, N-Tes. *Cancer Res.* 2001 (18896–8812).
 Li S, Meng H, Zhou F, val. Mit oRNA-132 18 frequently down-
- 24. Li S, Meng H, Zhou F, val. Mi oRNA-132 is frequently downregulated in ductal vacino, visitiu (DCIS) of breast and acts as a tumor suppressence of inhibiting cell probaration. *Pathol Res Pract.* 2013;209:176-6.
- Li Y, Wang Y, Yu D, eal. miR-146b-op inhibits glioma migration and invasion by targeting N P16. *Cancer Lett.* 2013;339(2):260–269.
- Fill are JL, VanMeter T, Broaddus WC. Membrane-type matrix relalloproteinases (MT-MMPs): expression and function during glioma vasion. J Neuropeol. 2001;53(2):187–202.
- Y, Chopp M, Jeeng X, Katakowski M, Buller B, Jiang F. MiR-145 recurses ADAM1 expression and inhibits in vitro migration and invasion of the presence of the second second

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

Dovepress

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

3218 submit your manuscript | www.dovepress.cor Dovepress